Skip to main content

Take Two of These

Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.

Written byBob Grant
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00

A tuberculosis patient in Cape Town, South Africa, receives a dose of the standard four-drug treatment regimen. ERIC MILLER (PANOS)

Living with a severe illness like cancer, HIV, or tuberculosis (TB) means taking many medications on a daily basis. With HIV, it’s a cocktail of antiretrovirals that target pathways for viral replication or entry into host cells. For TB, a slew of antibiotics strikes multiple blows to the infecting bacterial population in an attempt to eliminate even the most resistant individuals. And in cancer, chemotherapeutics are administered in layers, with different compounds attacking various facets of tumor growth.

Historically, clinical combination therapies have been cobbled together out of medicines that were approved for use individually. TB patients, for example, have been treated with a suite of antibiotics for more than 50 years, with substitutions and additions of approved medications being made to the regimen as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Related Topics

Published In

Related articles background image
The Scientist Digest cover September 2026
September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue
Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Alamar Biosciences logo
Best Practices for qPCR Assay Design and Optimization

Best Practices for qPCR Assay Design and Optimization

Bio-Rad
Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

bioxcell
Scientist reviewing cellular and molecular data on a computer in a laboratory.

Building Translation-Ready Biomarkers with Connected Workflows

Danaher Logo

Products

Closeup image of a multi channel pipette dispensing pink liquid into a 96-well plate.

The ASSIST PLUS pipetting robot for affordable workflow automation

Integra Logo
Single cells in suspension

Rapidly isolate primary cells and make uniform single-cell suspensions with Corning® Cell Strainers

Corning logo
Abstract image representing cell membranes linked together.

CellBrite® Steady Membrane Stain: Cell surface staining built for real-time imaging

Biotium
sino biological logo

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays